Rami B. Ibrahim

Rami B. Ibrahim

Auto-generated profile, based on publicly available information

Rami B. Ibrahim

Department of Pharmacy, Karmanos Cancer Institute, 4100 John R, Detroit, MI 48201-2013, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
RIRami B. Ibrahim
Rami B. Ibrahim
CLChin Liu
Chin Liu
SCSimon M. Cronin
Simon M. Cronin
BMBridgette C. Murphy
Bridgette C. Murphy
RCRaymond Cha
Raymond Cha
DEDavid J. Edwards
David J. Edwards

1 September 2011 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
JBJames A Barclay
James A Barclay
SZStamatina E Ziemba
Stamatina E Ziemba
RIRami B Ibrahim
Rami B Ibrahim
OBJECTIVE To present a comprehensive review of dapsone-induced methemoglobinemia and its management. DATA SOURCES Literature retrieval was accessed through MEDLINE (1966-March 2011), Cochrane Library, and EMBASE, using the terms dapsone and methemoglobinemia. STUDY SELECTION AND DATA EXTRACTION All case reports, small case series, and randomized controlled trials published in English were evaluated. Because of the absence of comprehensive updates on this topic since 1996, publications between 1997 and March 2011 were included in this review. DATA SYNTHESIS Between 1997 and March 2011, the majority of publications describing methemoglobinemia associated with dapsone use reported this adverse effect at therapeutic doses. Excluding overdose situations, 18 described symptomatic dapsone-associated methemoglobinemia and clinical presentation ranging from cyanosis to dyspnea. In almost all of the accounts, patients had a concurrent event such as anemia or pneumonia, suggesting an interplay between these comorbidities and the onset of symptomatic methemoglobinemia. Delayed hemolytic anemia was seen in patients with high methemoglobin levels at presentation. Management in most cases consisted of administration of methylene blue. Overall, most reports described a successful outcome, and no mortality resulted from methemoglobinemia associated with therapeutic use. CONCLUSIONS Clinicians should recognize methemoglobinemia as an adverse effect associated with dapsone use and the potential factors that precipitate it. They should also know how to promptly and effectively manage this event.


25 May 2009 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
EPE Peres
E Peres
JLJ E Levine
J E Levine
YKY A Khaled
Y A Khaled
RIR B Ibrahim
R B Ibrahim
TBT M Braun
T M Braun
MAM H Abidi
M H Abidi
Reduced-intensity conditioning (RIC) extends hematopoietic stem cell transplants (HSCT) to elderly or debilitated patients who are not candidates for HSCT. The incidence and outcomes of cardiac complications have been reported following myeloablative HSCT. We assessed the incidence and outcomes of cardiac complications in 278 recipients of RIC from July 2000 to July 2006. All patients received conditioning with BU, fludarabine and TBI. Patients were evaluated from conditioning therapy until 100 days after HSCT. Median age was 56 years. Cardiac events were defined as either one or more of the following: arrhythmias, myocardial infarction or congestive heart failure. Twenty-five patients developed arrhythmias at a median of 3 days post transplant, in 19 patients hemodynamic compromise occurred and mechanical ventilation was required in 15 patients. The arrhythmias included atrial fibrillation (n=17), atrial flutter (n=6) and supraventricular tachycardia (n=2). Troponin was elevated in 12 out of 25 patients. The mean brain natriuretic peptide was 679. All patients converted to a normal rhythm by medical therapy at a median of 2 days. Recurrence of arrhythmia occurred in 76% of patients. Day 100 mortality was 40% in this group. A history of high-dose anthracycline treatment and a low ejection fraction were risk factors for the development of cardiac complications.

6 July 2007 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
MAMuneer H. Abidi
Muneer H. Abidi
ITIsaacson Tove
Isaacson Tove
RIRami B. Ibrahim
Rami B. Ibrahim
DMDan Maria
Dan Maria
EPEdward Peres
Edward Peres

1 February 2000 in Life Sciences
Verified
Journal Article
Closed access
RIRami B. Ibrahim
Rami B. Ibrahim
JWJacquelyn G. Wilson
Jacquelyn G. Wilson
MTMary E. Thorsby
Mary E. Thorsby
DEDavid J. Edwards
David J. Edwards